GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Hikma Pharmaceuticals PLC (LSE:HIK) » Definitions » Gross Margin %

Hikma Pharmaceuticals (LSE:HIK) Gross Margin % : 46.62% (As of Dec. 2023)


View and export this data going back to 2005. Start your Free Trial

What is Hikma Pharmaceuticals Gross Margin %?

Gross Margin % is calculated as gross profit divided by its revenue. Hikma Pharmaceuticals's Gross Profit for the six months ended in Dec. 2023 was £533 Mil. Hikma Pharmaceuticals's Revenue for the six months ended in Dec. 2023 was £1,144 Mil. Therefore, Hikma Pharmaceuticals's Gross Margin % for the quarter that ended in Dec. 2023 was 46.62%.


The historical rank and industry rank for Hikma Pharmaceuticals's Gross Margin % or its related term are showing as below:

LSE:HIK' s Gross Margin % Range Over the Past 10 Years
Min: 48.35   Med: 50.64   Max: 57.15
Current: 48.35


During the past 13 years, the highest Gross Margin % of Hikma Pharmaceuticals was 57.15%. The lowest was 48.35%. And the median was 50.64%.

LSE:HIK's Gross Margin % is ranked better than
53.43% of 990 companies
in the Drug Manufacturers industry
Industry Median: 46.74 vs LSE:HIK: 48.35

Hikma Pharmaceuticals had a gross margin of 46.62% for the quarter that ended in Dec. 2023 => Durable competitive advantage

The 5-Year average Growth Rate of Gross Margin for Hikma Pharmaceuticals was -0.70% per year.


Hikma Pharmaceuticals Gross Margin % Historical Data

The historical data trend for Hikma Pharmaceuticals's Gross Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Hikma Pharmaceuticals Gross Margin % Chart

Hikma Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Gross Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 49.30 51.30 50.96 49.19 48.35

Hikma Pharmaceuticals Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Gross Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 51.23 50.37 48.08 50.11 46.62

Competitive Comparison of Hikma Pharmaceuticals's Gross Margin %

For the Drug Manufacturers - Specialty & Generic subindustry, Hikma Pharmaceuticals's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Hikma Pharmaceuticals's Gross Margin % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Hikma Pharmaceuticals's Gross Margin % distribution charts can be found below:

* The bar in red indicates where Hikma Pharmaceuticals's Gross Margin % falls into.



Hikma Pharmaceuticals Gross Margin % Calculation

Gross Margin is the percentage of Gross Profit out of sales or Revenue.

Hikma Pharmaceuticals's Gross Margin for the fiscal year that ended in Dec. 2023 is calculated as

Gross Margin % (A: Dec. 2023 )=Gross Profit (A: Dec. 2023 ) / Revenue (A: Dec. 2023 )
=1098.1 / 2271.25
=(Revenue - Cost of Goods Sold) / Revenue
=(2271.25 - 1173.15) / 2271.25
=48.35 %

Hikma Pharmaceuticals's Gross Margin for the quarter that ended in Dec. 2023 is calculated as


Gross Margin % (Q: Dec. 2023 )=Gross Profit (Q: Dec. 2023 ) / Revenue (Q: Dec. 2023 )
=533.3 / 1143.92
=(Revenue - Cost of Goods Sold) / Revenue
=(1143.92 - 610.67) / 1143.92
=46.62 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


Hikma Pharmaceuticals  (LSE:HIK) Gross Margin % Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

Hikma Pharmaceuticals had a gross margin of 46.62% for the quarter that ended in Dec. 2023 => Durable competitive advantage


Be Aware

If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.


Hikma Pharmaceuticals Gross Margin % Related Terms

Thank you for viewing the detailed overview of Hikma Pharmaceuticals's Gross Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Hikma Pharmaceuticals (LSE:HIK) Business Description

Traded in Other Exchanges
Address
1 New Burlington Place, London, GBR, W1S 2HR
Hikma Pharmaceuticals PLC is engaged in the development, manufacture, and marketing of a broad range of generic, branded, and in-licensed pharmaceutical products. The firm operates in three segments: injectables, generics, and branded. The majority of the company's sales are based in the U.S. and to a lesser degree in the Middle East, North Africa, and Europe.

Hikma Pharmaceuticals (LSE:HIK) Headlines

No Headlines